Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

No abstract is available for this paper.

• Publication year

  2015

• Venue

  British Journal of Haematology

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.13323PMID 25733005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Applications of Pathology-Assisted Image Analysis of Immunohistochemistry-Based Biomarkers in Oncology

  2014cited by this paper
• Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

  2012cited by this paper
• Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.

  2011cited by this paper
• An innovative, web-based reporting system for serious adverse events developed by the cancer therapy evaluation program (CTEP), National Cancer Institute (NCI)

  2011cited by this paper
• Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

  2011cited by this paper
• Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma.

  2011cited by this paper
• Abstract A196: Development, validation, and clinical implementation of a peripheral blood RT-PCR pharmacodynamic assay for MLN4924, an investigational small molecule inhibitor of NEDD8-activating enzyme (NAE).

  2011cited by this paper
• MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study.

  2011cited by this paper
• MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.

  2011cited by this paper
• Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer

  2011cited by this paper
• Azacitidine/Decitabine Synergism with the NEDD8-Activating Enzyme Inhibitor MLN4924 in Pre-Clinical AML Models

  2011cited by this paper
• Cul1 expression is increased in early stages of human melanoma

  2010cited by this paper
• The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.

  2010cited by this paper
• European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

  2010cited by this paper
• MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

  2010cited by this paper
• A Cancer Survivorship Study of Perceptions Among Leukemia Patients In the Acute, Extended, and Permanent Survival Phases.

  2010cited by this paper
• Disrupting NEDD8-Mediated Protein Turnover with MLN4924 Significantly Augments the Efficacy of Cytarabine

  2010cited by this paper
• Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

  2010cited by this paper
• Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression.

  2010cited by this paper
• Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

  2010cited by this paper
• NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.

  2010cited by this paper
• The ubiquitous nature of cancer: the role of the SCFFbw7 complex in development and transformation

  2010cited by this paper
• Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer

  2009influential reference
• Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin.

  2009cited by this paper
• Molecular Pathways Targeting NEDD 8-Activated Cullin-RING Ligases for the Treatment of Cancer

  2009cited by this paper
• Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

  2009influential reference
• The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

  2009cited by this paper
• An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

  2009cited by this paper
• Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

  2009cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• Ubiquitin and ubiquitin-like proteins in protein regulation.

  2007cited by this paper
• Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248

  2007influential reference
• A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

  2007cited by this paper
• Nuclear factor-kappaB in cancer development and progression.

  2006cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006influential reference
• Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

  2006influential reference
• Nuclear factor-κB in cancer development and progression

  2006cited by this paper
• Function and regulation of cullin–RING ubiquitin ligases

  2005cited by this paper
• The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle*

  2005influential reference
• Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture).

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system.

  2004cited by this paper
• The development of proteasome inhibitors as anticancer drugs.

  2004cited by this paper
• Phase II trial of bortezomib for patients with advanced renal cell carcinoma.

  2004influential reference
• Deregulated degradation of the cdk inhibitor p27 and malignant transformation.

  2003cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

  2002cited by this paper
• Skp2 is oncogenic and overexpressed in human cancers

  2001cited by this paper
• Nedd8 Modification of Cul-1 Activates SCFβTrCP-Dependent Ubiquitination of IκBα

  2000cited by this paper
• A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination.

  2000cited by this paper
• Identification of the Activating and Conjugating Enzymes of the NEDD8 Conjugation Pathway*

  1999cited by this paper

• DCN-type NEDD8 E3 ligases: Structure, biological function and small-molecule inhibitor.

  2026cites this paper
• Pevonedistat targeting NEDDylation activating enzyme for human diseases: Underlying mechanisms, clinical studies, and future directions.

  2026cites this paper
• Molecularly targeted therapy and immunotherapy in leukemias

  2026cites this paper
• Post-translational modification networks in tumor radiosensitivity: mechanistic insights and therapeutic opportunities

  2026cites this paper
• Ubiquitin proteasome system (UPS): a crucial determinant of the epigenetic landscape in cancer.

  2025cites this paper
• A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome

  2025cites this paper
• Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer

  2025cites this paper
• Design and Synthesis of Novel 5,6,7,8-Tetrahydropyrido[2,3-D]pyrimidine Derivatives as VCP/p97 Inhibitors for the Treatment of Acute Myeloid Leukemia (AML)

  2025cites this paper
• Neddylation Regulates Mitochondrial Dynamics and Turnover in the Adult Heart

  2025cites this paper
• Targeting autophagy and metabolism for ewing sarcoma

  2025cites this paper
• Neddylation and MASLD: From Pathophysiology to Therapy

  2025cites this paper
• Neddylation: from regulatory mechanisms to clinical implications in cancer.

  2025cites this paper
• Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities

  2025cites this paper
• TRAF2 associates with cullin neddylation complex assembly

  2024cites this paper
• Centipeda minima extracts and the active sesquiterpene lactones have therapeutic efficacy in non-small cell lung cancer by suppressing Skp2/p27 signaling pathway.

  2024cites this paper
• Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

  2024cites this paper
• Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia

  2024cites this paper
• A Novel Approach to Explore Metabolic Diseases: Neddylation.

  2024cites this paper
• Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications.

  2024cites this paper
• Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

  2024cites this paper
• DCUN1D1 and neddylation: Potential targets for cancer therapy.

  2024cites this paper
• Inhibiting neddylation: A new strategy for tumor therapy

  2024cites this paper
• From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies

  2024cites this paper
• Protein neddylation and its role in health and diseases

  2024cites this paper
• Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways

  2024cites this paper
• ncRNAs Orchestrate Chemosensitivity Induction by Neddylation Blockades

  2024cites this paper
• The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer

  2024cites this paper
• A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia

  2024cites this paper
• Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

  2023cites this paper
• Prognostic biomarkers and molecular pathways mediating Helicobacter pylori–induced gastric cancer: a network-biology approach

  2023cites this paper
• A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

  2023cites this paper
• Rational design and development of novel NAE inhibitors for the treatment of pancreatic cancer

  2023cites this paper
• Targeting cullin neddylation for cancer and fibrotic diseases

  2023cites this paper
• Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712

  2023cites this paper
• Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells

  2023cites this paper
• Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions

  2023cites this paper
• Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia

  2023cites this paper
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

  2023cites this paper
• [Treating high-risk myelodysplastic syndromes].

  2023cites this paper
• NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells

  2023cites this paper
• The COP9 signalosome reduces neuroinflammation and attenuates ischemic neuronal stress in organotypic brain slice culture model

  2023cites this paper
• Host Cell Neddylation Facilitates Alphaherpesvirus Entry in a Virus-Specific and Cell-Dependent Manner

  2022cites this paper
• SOHO State of the Art and Next Questions: Treatment of Higher-Risk Myelodysplastic Syndromes.

  2022cites this paper
• High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

  2022cites this paper
• The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?

  2022cites this paper
• Review: New horizons in retinoblastoma treatment: an updated review article

  2022cites this paper
• New Therapeutic Strategies for Adult Acute Myeloid Leukemia

  2022cites this paper
• VCP inhibition induces an unfolded protein response and apoptosis in human acute myeloid leukemia cells

  2022cites this paper
• The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA

  2022cites this paper
• Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review

  2022cites this paper
• Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

  2022cites this paper
• New Approaches to Myelodysplastic Syndrome Treatment

  2022cites this paper
• Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway

  2022cites this paper
• Catalyst-Controlled, Site-Selective Sulfamoylation of Carbohydrate Derivatives.

  2022cites this paper
• ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration

  2022cites this paper
• Hepatic neddylation deficiency triggers fatal liver injury via inducing NF-κB-inducing kinase in mice

  2022cites this paper
• Regulation of Nucleolar Activity by MYC

  2022cites this paper
• Cdk2 suppresses IL‐23 expression and the onset of severe acute pancreatitis

  2022cites this paper
• Inhibition of Neddylation Suppresses Osteoclast Differentiation and Function In Vitro and Alleviates Osteoporosis In Vivo

  2022cites this paper
• PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression

  2022cites this paper
• Aberrant SKP1 Expression: Diverse Mechanisms Impacting Genome and Chromosome Stability

  2022cites this paper
• MLN4924 Treatment Diminishes Excessive Lipid Storage in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Stimulating Hepatic Mitochondrial Fatty Acid Oxidation and Lipid Metabolites

  2022cites this paper
• Neddylation and anti-tumor immunity

  2021cites this paper
• Myeloid neddylation targets IRF7 and promotes host innate immunity against RNA viruses

  2021cites this paper
• TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia

  2021cites this paper
• Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

  2021cites this paper
• Pevonedistat attenuates cisplatin‐induced nephrotoxicity in mice by downregulating the release of inflammatory mediators

  2021cites this paper
• Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition

  2021cites this paper
• E1 Enzymes as Therapeutic Targets in Cancer

  2021cites this paper
• Myelodysplastic Syndromes: A New Decade.

  2021cites this paper
• Inhibition of NAE‐dependent protein hyper‐NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease

  2021cites this paper
• NEDD9 overexpression: Prognostic and guidance value in acute myeloid leukaemia

  2021cites this paper
• Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer

  2021cites this paper
• The SCF Complex Is Essential to Maintain Genome and Chromosome Stability

  2021cites this paper
• Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis

  2021cites this paper
• Investigational new drugs against glioblastoma

  2021cites this paper
• Neddylation Alleviates Methicillin-Resistant Staphylococcus aureus Infection by Inducing Macrophage Reactive Oxygen Species Production

  2021cites this paper
• A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors

  2021cites this paper
• Advances in Cancer Treatment by Targeting the Neddylation Pathway

  2021cites this paper
• Desmosomal COP9 regulates proteome degradation in arrhythmogenic right ventricular dysplasia/cardiomyopathy

  2021cites this paper
• Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

  2021cites this paper
• A preview of select articles

  2021cites this paper
• Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms

  2021cites this paper
• Progress Update in Pediatric Renal Tumors

  2021cites this paper
• Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.

  2021cites this paper
• Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?

  2021cites this paper
• Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia

  2021cites this paper
• Strategies targeting FLT3 beyond the kinase inhibitors.

  2021cites this paper
• Neddylation Regulates Macrophages and Implications for Cancer Therapy

  2021cites this paper
• Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective

  2021cites this paper
• Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation.

  2021cites this paper
• Emerging drugs for the treatment of chronic myelomonocytic leukemia

  2020cites this paper
• Emerging treatment options for patients with high-risk myelodysplastic syndrome

  2020cites this paper
• Neddylation inhibitor MLN4924 has anti‐HBV activity via modulating the ERK‐HNF1α‐C/EBPα‐HNF4α axis

  2020cites this paper
• The Role of Cullin-RING Ligases in Striated Muscle Development, Function, and Disease

  2020cites this paper
• Targeting Protein Neddylation for Cancer Therapy.

  2020cites this paper
• How we manage adults with myelodysplastic syndrome

  2020cites this paper
• Allogeneic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes and Prevention of Relapse.

  2020cites this paper
• Characterization of Plasmodium falciparum NEDD8 and identification of cullins as its substrates

  2020cites this paper
• Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?

  2020cites this paper